ArticleBlood advances2026
Bispecific antibodies are becoming the preferred standard of care in relapsed/refractory multiple myeloma.
Murali JanakiramPubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it